Late-stage interventional trials will evaluate personalized approaches to existing care and novel targeted therapies
Endpoint Health, the first targeted therapeutics company focused on integrated solutions for critical illnesses, today announced a new strategic partnership with Vanderbilt University Medical Center (VUMC) to create the first precision medicine clinical trial network focused on late-stage clinical trials in critical illness. The network will combine leading critical illness researchers, trialists and premier medical centers from across the country to create a sustained system for conducting phase II and III interventional trials intended to validate precision medicine technologies, therapies, and deployable patient-centric care approaches. It will prioritize trials investigating promising precision-driven interventions to prevent or treat critical illnesses such as sepsis and acute respiratory distress syndrome (ARDS), which are the most expensive conditions to treat in the hospital setting and are associated with half of U.S. hospital mortality.
“Endpoint Health envisions a future where clinicians